Santersus AG Completes Series A Financing and Announces Strategic Collaboration with Terumo Corporation

Santersus AG Announces Advancement of NucleoCapture into Pivotal Clinical Development strengthened by Strategic Collaboration with Terumo.

Series A Funding Success

Zurich, Switzerland, 1st Dec 2025 – Santersus AG has completed its Series A financing. The round was led by Norcliffe, a UK life sciences fund, with support from Terumo Ventures. This investment will help advance Santersus’ NucleoCapture into pivotal clinical trials. It will also accelerate progress across the company’s broader pipeline.

Santersus has also formed a strategic collaboration with Terumo Blood and Cell Technologies. Together, they aim to advance NucleoCapture™ for sepsis treatment. Sepsis kills 11 million people worldwide each year, so new solutions are urgently needed. The partnership combines Santersus’ first-in-class NucleoCapture blood purification device with Terumo BCT’s Spectra Optia Apheresis System. This creates a new therapeutic apheresis approach designed to remove neutrophil extracellular traps (NETs), which drive inflammation and organ failure in sepsis. NucleoCapture already holds two U.S. FDA Breakthrough Device Designations, including one for sepsis treatment.

Global Sepsis Trial Launch

Under this collaboration, Santersus will lead the pivotal NUC-CAP clinical trial. The study will run in the United States, United Kingdom, Switzerland, and several European countries. Meanwhile, Terumo BCT will support the program’s clinical development. Terumo Ventures has also invested in Santersus’ Series A round to help speed the development of this critical technology.

“Therapeutic apheresis has untapped potential to address serious unmet medical needs,” said Veerle d’Haenens, General Manager of Global Therapy Innovations at Terumo Blood and Cell Technologies. “Our partnership with Santersus reflects our commitment to advancing innovative treatment options for critically ill patients.”

Expanding Autoimmune Pipeline

The Series A financing will also support Santersus’ preparation for pivotal trials in systemic lupus erythematosus (SLE). NucleoCapture has earned its second U.S. FDA Breakthrough Device Designation for treatment-refractory lupus. This SLE program targets a global market valued at approximately $4 billion. It will expand Santersus’ late-stage clinical pipeline and is expected to begin after the sepsis study launch.

Santersus is also adapting NucleoCapture for solid-organ transplantation. One program focuses on perfusing and repairing severely damaged donor livers before transplant. The global transplantation market may reach $61.5 billion by 2027. In addition, the company is advancing a lung-transplantation program designed to prevent primary graft dysfunction (PGD). These efforts highlight the wide potential of NucleoCapture across organ-transplant medicine.

Broader Clinical Development

Santersus is also moving forward with early-stage development of NucleoCapture for Alzheimer’s disease. An exploratory clinical study is under way to examine its effects on amyloid removal. The global Alzheimer’s therapeutics market is valued at nearly $5 billion and may double within the next decade.

Together, these programs show Santersus’ evolution into a multi-indication, late-stage clinical development company. With strong momentum across critical care, autoimmunity, transplantation, and neurodegeneration, Santersus is becoming a leading developer of NET-targeted therapeutic apheresis technologies.

About Santersus AG

Zurich-based Santersus AG is a biotechnology company developing NucleoCapture, a novel, patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs). NucleoCapture has received two U.S. FDA Breakthrough Device Designations: one for the treatment of sepsis and one for systemic lupus erythematosus. Santersus is advancing a diversified clinical pipeline across sepsis, systemic lupus erythematosus, solid-organ transplantation (liver and lung), and Alzheimer’s disease.

For more information, please visit www.santersus.com

Company Details

Organization: Santersus AG

Contact Person: Aleksander Zaporoztsev

Website: https://www.santersus.com

Email: info@santersus.com

Country: Switzerland

Release Id: 01122538172